BIO-GENE Technology Ltd is an Australian public biotechnology company that is developing a patent protected product platform as a new class of insecticides.
SOI: 132 Million. MC : $27 Million Share price : 20.5c Cash : $3.5 Million.
Strategic approach:
In-house Testing & Data Generation: • Suite of data now well developed, with compelling evidence of efficacy of Flavocide against key vector mosquito species
Progress Commercial Discussions Globally: • Now pursuing discussions with Corporates, NGO’s, Philanthropic & Gov Agencies • Progress Material Transfer Agreements (MTA’s) relevant to this Vector Control CD AB
Exclusive Partnership Arrangements: • Work to structure exclusive partnerships (similar to recent Grain Storage program with BASF)
Commercial Deals: • Progress towards more formal agreements and development plans with key partners to enable commercialisation of our technology.
"Given the nature of major public health problems such as malaria, potential partners range from big pharmaceutical companies to philanthropic organisations and major government departments. Names in the space include the Bill & Melinda Gates Foundation, the World Health Organisation and the US Department of Defense. “The list is huge, and we have a great opportunity to talk to those groups – particularly via connections through the experts at Purdue who are recognised as global leaders for this kind of research,” Jagger said. “A lot of those groups are putting in significant resources. And with the size of those potential partners they can also help fund us on that journey. So it’s a real golden ticket.”
While the breakthrough with Purdue marks another step forward for Bio-Gene, a consistent run of positive news-flow has attracted a steady pickup in investor interest during the second half of 2019. Discussing the recent share price momentum, Jagger said discussions with investors centred around the company’s approach to innovation, as well as steady stewardship of its capital base. “Investors have seen that we’re beginning to de-risk the technology, and show where the potential lies,” he said. “I think we’ve also been very good at looking after our funds. We haven’t raised any additional funds since our IPO in 2017, and we’ve still got $4m in the bank. “It’s about leveraging our ability to build data and knowledge with other organisations and companies. We’re starting to put pieces together with the potential to deliver some much-needed tech in the world."
